nodes	percent_of_prediction	percent_of_DWPC	metapath
Eletriptan—CYP2A6—lung cancer	0.277	0.729	CbGaD
Eletriptan—ABCB1—lung cancer	0.103	0.271	CbGaD
Eletriptan—CYP2C19—Gefitinib—lung cancer	0.0208	0.0559	CbGbCtD
Eletriptan—CYP2C19—Teniposide—lung cancer	0.0202	0.0542	CbGbCtD
Eletriptan—PTGS1—Etoposide—lung cancer	0.0184	0.0494	CbGbCtD
Eletriptan—ABCB1—Topotecan—lung cancer	0.0184	0.0493	CbGbCtD
Eletriptan—CYP2C9—Gefitinib—lung cancer	0.0173	0.0465	CbGbCtD
Eletriptan—ABCB1—Gefitinib—lung cancer	0.0168	0.0451	CbGbCtD
Eletriptan—CYP2C9—Teniposide—lung cancer	0.0168	0.0451	CbGbCtD
Eletriptan—CYP2D6—Gefitinib—lung cancer	0.0158	0.0425	CbGbCtD
Eletriptan—ABCB1—Vinorelbine—lung cancer	0.0129	0.0347	CbGbCtD
Eletriptan—CYP2D6—Vinorelbine—lung cancer	0.0122	0.0327	CbGbCtD
Eletriptan—CYP3A4—Topotecan—lung cancer	0.011	0.0295	CbGbCtD
Eletriptan—ABCB1—Crizotinib—lung cancer	0.0103	0.0276	CbGbCtD
Eletriptan—CYP3A4—Gefitinib—lung cancer	0.0101	0.027	CbGbCtD
Eletriptan—ABCB1—Gemcitabine—lung cancer	0.0101	0.027	CbGbCtD
Eletriptan—ABCB1—Erlotinib—lung cancer	0.00993	0.0267	CbGbCtD
Eletriptan—CYP3A4—Teniposide—lung cancer	0.00975	0.0262	CbGbCtD
Eletriptan—CYP2C9—Paclitaxel—lung cancer	0.00936	0.0251	CbGbCtD
Eletriptan—CYP2D6—Erlotinib—lung cancer	0.00935	0.0251	CbGbCtD
Eletriptan—ABCB1—Paclitaxel—lung cancer	0.00909	0.0244	CbGbCtD
Eletriptan—ABCB1—Irinotecan—lung cancer	0.00897	0.0241	CbGbCtD
Eletriptan—ABCB1—Vinblastine—lung cancer	0.00797	0.0214	CbGbCtD
Eletriptan—CYP3A4—Vinorelbine—lung cancer	0.00775	0.0208	CbGbCtD
Eletriptan—CYP2C9—Cisplatin—lung cancer	0.00753	0.0202	CbGbCtD
Eletriptan—CYP2D6—Vinblastine—lung cancer	0.00751	0.0202	CbGbCtD
Eletriptan—ABCB1—Cisplatin—lung cancer	0.00731	0.0196	CbGbCtD
Eletriptan—ABCB1—Etoposide—lung cancer	0.00718	0.0193	CbGbCtD
Eletriptan—ABCB1—Docetaxel—lung cancer	0.00657	0.0176	CbGbCtD
Eletriptan—CYP3A4—Crizotinib—lung cancer	0.00617	0.0166	CbGbCtD
Eletriptan—CYP3A4—Erlotinib—lung cancer	0.00595	0.016	CbGbCtD
Eletriptan—CYP3A4—Paclitaxel—lung cancer	0.00544	0.0146	CbGbCtD
Eletriptan—CYP3A4—Irinotecan—lung cancer	0.00537	0.0144	CbGbCtD
Eletriptan—ABCB1—Doxorubicin—lung cancer	0.0049	0.0132	CbGbCtD
Eletriptan—CYP3A4—Vinblastine—lung cancer	0.00478	0.0128	CbGbCtD
Eletriptan—ABCB1—Methotrexate—lung cancer	0.00474	0.0127	CbGbCtD
Eletriptan—CYP2D6—Doxorubicin—lung cancer	0.00461	0.0124	CbGbCtD
Eletriptan—CYP3A4—Etoposide—lung cancer	0.0043	0.0116	CbGbCtD
Eletriptan—CYP3A4—Docetaxel—lung cancer	0.00394	0.0106	CbGbCtD
Eletriptan—CYP3A4—Doxorubicin—lung cancer	0.00293	0.00788	CbGbCtD
Eletriptan—Sumatriptan—ABCG2—lung cancer	0.000495	0.39	CrCbGaD
Eletriptan—Almotriptan—CYP2E1—lung cancer	0.000408	0.322	CrCbGaD
Eletriptan—Sumatriptan—ABCB1—lung cancer	0.000206	0.162	CrCbGaD
Eletriptan—Thioridazine—CYP2E1—lung cancer	0.00016	0.126	CrCbGaD
Eletriptan—Cough—Docetaxel—lung cancer	6.74e-05	0.000411	CcSEcCtD
Eletriptan—Angina pectoris—Doxorubicin—lung cancer	6.74e-05	0.000411	CcSEcCtD
Eletriptan—Insomnia—Paclitaxel—lung cancer	6.72e-05	0.00041	CcSEcCtD
Eletriptan—Epistaxis—Methotrexate—lung cancer	6.72e-05	0.000409	CcSEcCtD
Eletriptan—Hypersensitivity—Irinotecan—lung cancer	6.72e-05	0.000409	CcSEcCtD
Eletriptan—Convulsion—Docetaxel—lung cancer	6.69e-05	0.000408	CcSEcCtD
Eletriptan—Paraesthesia—Paclitaxel—lung cancer	6.68e-05	0.000407	CcSEcCtD
Eletriptan—Hypertension—Docetaxel—lung cancer	6.67e-05	0.000406	CcSEcCtD
Eletriptan—Bronchitis—Doxorubicin—lung cancer	6.65e-05	0.000405	CcSEcCtD
Eletriptan—Dyspnoea—Paclitaxel—lung cancer	6.63e-05	0.000404	CcSEcCtD
Eletriptan—Somnolence—Paclitaxel—lung cancer	6.61e-05	0.000403	CcSEcCtD
Eletriptan—Decreased appetite—Etoposide—lung cancer	6.59e-05	0.000402	CcSEcCtD
Eletriptan—Arthralgia—Docetaxel—lung cancer	6.57e-05	0.000401	CcSEcCtD
Eletriptan—Myalgia—Docetaxel—lung cancer	6.57e-05	0.000401	CcSEcCtD
Eletriptan—Nausea—Vinorelbine—lung cancer	6.57e-05	0.0004	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Etoposide—lung cancer	6.55e-05	0.000399	CcSEcCtD
Eletriptan—Dyspepsia—Paclitaxel—lung cancer	6.54e-05	0.000399	CcSEcCtD
Eletriptan—Body temperature increased—Cisplatin—lung cancer	6.54e-05	0.000399	CcSEcCtD
Eletriptan—Asthenia—Irinotecan—lung cancer	6.54e-05	0.000399	CcSEcCtD
Eletriptan—Fatigue—Etoposide—lung cancer	6.54e-05	0.000398	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	6.53e-05	0.000398	CcSEcCtD
Eletriptan—Constipation—Etoposide—lung cancer	6.48e-05	0.000395	CcSEcCtD
Eletriptan—Pain—Etoposide—lung cancer	6.48e-05	0.000395	CcSEcCtD
Eletriptan—Decreased appetite—Paclitaxel—lung cancer	6.46e-05	0.000394	CcSEcCtD
Eletriptan—Dry mouth—Docetaxel—lung cancer	6.43e-05	0.000392	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Paclitaxel—lung cancer	6.42e-05	0.000391	CcSEcCtD
Eletriptan—Fatigue—Paclitaxel—lung cancer	6.41e-05	0.000391	CcSEcCtD
Eletriptan—Pollakiuria—Doxorubicin—lung cancer	6.39e-05	0.000389	CcSEcCtD
Eletriptan—Asthenia—Gemcitabine—lung cancer	6.37e-05	0.000388	CcSEcCtD
Eletriptan—Pain—Paclitaxel—lung cancer	6.36e-05	0.000387	CcSEcCtD
Eletriptan—Constipation—Paclitaxel—lung cancer	6.36e-05	0.000387	CcSEcCtD
Eletriptan—Confusional state—Docetaxel—lung cancer	6.35e-05	0.000387	CcSEcCtD
Eletriptan—Pharyngitis—Methotrexate—lung cancer	6.34e-05	0.000387	CcSEcCtD
Eletriptan—Urinary tract disorder—Methotrexate—lung cancer	6.31e-05	0.000385	CcSEcCtD
Eletriptan—Oedema—Docetaxel—lung cancer	6.3e-05	0.000384	CcSEcCtD
Eletriptan—Weight increased—Doxorubicin—lung cancer	6.29e-05	0.000384	CcSEcCtD
Eletriptan—Pruritus—Gemcitabine—lung cancer	6.28e-05	0.000383	CcSEcCtD
Eletriptan—Urethral disorder—Methotrexate—lung cancer	6.27e-05	0.000382	CcSEcCtD
Eletriptan—Weight decreased—Doxorubicin—lung cancer	6.26e-05	0.000381	CcSEcCtD
Eletriptan—Feeling abnormal—Etoposide—lung cancer	6.25e-05	0.000381	CcSEcCtD
Eletriptan—Hyperglycaemia—Doxorubicin—lung cancer	6.24e-05	0.00038	CcSEcCtD
Eletriptan—Diarrhoea—Irinotecan—lung cancer	6.24e-05	0.00038	CcSEcCtD
Eletriptan—Gastrointestinal pain—Etoposide—lung cancer	6.2e-05	0.000378	CcSEcCtD
Eletriptan—Shock—Docetaxel—lung cancer	6.2e-05	0.000378	CcSEcCtD
Eletriptan—Nervous system disorder—Docetaxel—lung cancer	6.18e-05	0.000377	CcSEcCtD
Eletriptan—Drowsiness—Doxorubicin—lung cancer	6.17e-05	0.000376	CcSEcCtD
Eletriptan—Visual impairment—Methotrexate—lung cancer	6.16e-05	0.000375	CcSEcCtD
Eletriptan—Tachycardia—Docetaxel—lung cancer	6.15e-05	0.000375	CcSEcCtD
Eletriptan—Feeling abnormal—Paclitaxel—lung cancer	6.13e-05	0.000373	CcSEcCtD
Eletriptan—Skin disorder—Docetaxel—lung cancer	6.12e-05	0.000373	CcSEcCtD
Eletriptan—Hypersensitivity—Cisplatin—lung cancer	6.1e-05	0.000372	CcSEcCtD
Eletriptan—Gastrointestinal pain—Paclitaxel—lung cancer	6.08e-05	0.00037	CcSEcCtD
Eletriptan—Diarrhoea—Gemcitabine—lung cancer	6.08e-05	0.00037	CcSEcCtD
Eletriptan—Neuropathy peripheral—Doxorubicin—lung cancer	6.04e-05	0.000368	CcSEcCtD
Eletriptan—Dizziness—Irinotecan—lung cancer	6.03e-05	0.000367	CcSEcCtD
Eletriptan—Urticaria—Etoposide—lung cancer	6.02e-05	0.000367	CcSEcCtD
Eletriptan—Stomatitis—Doxorubicin—lung cancer	6.01e-05	0.000366	CcSEcCtD
Eletriptan—Anorexia—Docetaxel—lung cancer	6.01e-05	0.000366	CcSEcCtD
Eletriptan—Abdominal pain—Etoposide—lung cancer	5.99e-05	0.000365	CcSEcCtD
Eletriptan—Body temperature increased—Etoposide—lung cancer	5.99e-05	0.000365	CcSEcCtD
Eletriptan—Conjunctivitis—Doxorubicin—lung cancer	5.99e-05	0.000365	CcSEcCtD
Eletriptan—Tinnitus—Methotrexate—lung cancer	5.96e-05	0.000363	CcSEcCtD
Eletriptan—Asthenia—Cisplatin—lung cancer	5.94e-05	0.000362	CcSEcCtD
Eletriptan—Sweating—Doxorubicin—lung cancer	5.91e-05	0.00036	CcSEcCtD
Eletriptan—Urticaria—Paclitaxel—lung cancer	5.91e-05	0.00036	CcSEcCtD
Eletriptan—Hypotension—Docetaxel—lung cancer	5.89e-05	0.000359	CcSEcCtD
Eletriptan—Body temperature increased—Paclitaxel—lung cancer	5.88e-05	0.000358	CcSEcCtD
Eletriptan—Abdominal pain—Paclitaxel—lung cancer	5.88e-05	0.000358	CcSEcCtD
Eletriptan—Epistaxis—Doxorubicin—lung cancer	5.82e-05	0.000354	CcSEcCtD
Eletriptan—Vomiting—Irinotecan—lung cancer	5.8e-05	0.000353	CcSEcCtD
Eletriptan—Sinusitis—Doxorubicin—lung cancer	5.78e-05	0.000353	CcSEcCtD
Eletriptan—Immune system disorder—Methotrexate—lung cancer	5.77e-05	0.000352	CcSEcCtD
Eletriptan—Rash—Irinotecan—lung cancer	5.75e-05	0.00035	CcSEcCtD
Eletriptan—Dermatitis—Irinotecan—lung cancer	5.74e-05	0.00035	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Docetaxel—lung cancer	5.74e-05	0.00035	CcSEcCtD
Eletriptan—Chills—Methotrexate—lung cancer	5.74e-05	0.00035	CcSEcCtD
Eletriptan—Headache—Irinotecan—lung cancer	5.71e-05	0.000348	CcSEcCtD
Eletriptan—Insomnia—Docetaxel—lung cancer	5.7e-05	0.000347	CcSEcCtD
Eletriptan—Diarrhoea—Cisplatin—lung cancer	5.66e-05	0.000345	CcSEcCtD
Eletriptan—Paraesthesia—Docetaxel—lung cancer	5.66e-05	0.000345	CcSEcCtD
Eletriptan—Alopecia—Methotrexate—lung cancer	5.65e-05	0.000344	CcSEcCtD
Eletriptan—Vomiting—Gemcitabine—lung cancer	5.65e-05	0.000344	CcSEcCtD
Eletriptan—Bradycardia—Doxorubicin—lung cancer	5.64e-05	0.000343	CcSEcCtD
Eletriptan—Dyspnoea—Docetaxel—lung cancer	5.62e-05	0.000342	CcSEcCtD
Eletriptan—Somnolence—Docetaxel—lung cancer	5.6e-05	0.000341	CcSEcCtD
Eletriptan—Rash—Gemcitabine—lung cancer	5.6e-05	0.000341	CcSEcCtD
Eletriptan—Dermatitis—Gemcitabine—lung cancer	5.59e-05	0.000341	CcSEcCtD
Eletriptan—Hypersensitivity—Etoposide—lung cancer	5.59e-05	0.00034	CcSEcCtD
Eletriptan—Headache—Gemcitabine—lung cancer	5.56e-05	0.000339	CcSEcCtD
Eletriptan—Rhinitis—Doxorubicin—lung cancer	5.55e-05	0.000338	CcSEcCtD
Eletriptan—Dyspepsia—Docetaxel—lung cancer	5.55e-05	0.000338	CcSEcCtD
Eletriptan—Hypoaesthesia—Doxorubicin—lung cancer	5.51e-05	0.000336	CcSEcCtD
Eletriptan—Pharyngitis—Doxorubicin—lung cancer	5.49e-05	0.000335	CcSEcCtD
Eletriptan—Decreased appetite—Docetaxel—lung cancer	5.48e-05	0.000334	CcSEcCtD
Eletriptan—Hypersensitivity—Paclitaxel—lung cancer	5.48e-05	0.000334	CcSEcCtD
Eletriptan—Urinary tract disorder—Doxorubicin—lung cancer	5.47e-05	0.000333	CcSEcCtD
Eletriptan—Oedema peripheral—Doxorubicin—lung cancer	5.45e-05	0.000332	CcSEcCtD
Eletriptan—Dysgeusia—Methotrexate—lung cancer	5.45e-05	0.000332	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Docetaxel—lung cancer	5.44e-05	0.000332	CcSEcCtD
Eletriptan—Asthenia—Etoposide—lung cancer	5.44e-05	0.000332	CcSEcCtD
Eletriptan—Fatigue—Docetaxel—lung cancer	5.43e-05	0.000331	CcSEcCtD
Eletriptan—Urethral disorder—Doxorubicin—lung cancer	5.43e-05	0.000331	CcSEcCtD
Eletriptan—Nausea—Irinotecan—lung cancer	5.41e-05	0.00033	CcSEcCtD
Eletriptan—Constipation—Docetaxel—lung cancer	5.39e-05	0.000328	CcSEcCtD
Eletriptan—Pain—Docetaxel—lung cancer	5.39e-05	0.000328	CcSEcCtD
Eletriptan—Back pain—Methotrexate—lung cancer	5.38e-05	0.000328	CcSEcCtD
Eletriptan—Pruritus—Etoposide—lung cancer	5.36e-05	0.000327	CcSEcCtD
Eletriptan—Visual impairment—Doxorubicin—lung cancer	5.33e-05	0.000325	CcSEcCtD
Eletriptan—Asthenia—Paclitaxel—lung cancer	5.33e-05	0.000325	CcSEcCtD
Eletriptan—Nausea—Gemcitabine—lung cancer	5.27e-05	0.000321	CcSEcCtD
Eletriptan—Vomiting—Cisplatin—lung cancer	5.26e-05	0.000321	CcSEcCtD
Eletriptan—Pruritus—Paclitaxel—lung cancer	5.26e-05	0.000321	CcSEcCtD
Eletriptan—Rash—Cisplatin—lung cancer	5.22e-05	0.000318	CcSEcCtD
Eletriptan—Dermatitis—Cisplatin—lung cancer	5.21e-05	0.000318	CcSEcCtD
Eletriptan—Feeling abnormal—Docetaxel—lung cancer	5.19e-05	0.000316	CcSEcCtD
Eletriptan—Diarrhoea—Etoposide—lung cancer	5.19e-05	0.000316	CcSEcCtD
Eletriptan—Ill-defined disorder—Methotrexate—lung cancer	5.16e-05	0.000315	CcSEcCtD
Eletriptan—Tinnitus—Doxorubicin—lung cancer	5.16e-05	0.000315	CcSEcCtD
Eletriptan—Gastrointestinal pain—Docetaxel—lung cancer	5.15e-05	0.000314	CcSEcCtD
Eletriptan—Anaemia—Methotrexate—lung cancer	5.14e-05	0.000313	CcSEcCtD
Eletriptan—Flushing—Doxorubicin—lung cancer	5.14e-05	0.000313	CcSEcCtD
Eletriptan—Diarrhoea—Paclitaxel—lung cancer	5.09e-05	0.00031	CcSEcCtD
Eletriptan—Malaise—Methotrexate—lung cancer	5.02e-05	0.000306	CcSEcCtD
Eletriptan—Dizziness—Etoposide—lung cancer	5.01e-05	0.000306	CcSEcCtD
Eletriptan—Immune system disorder—Doxorubicin—lung cancer	5e-05	0.000305	CcSEcCtD
Eletriptan—Vertigo—Methotrexate—lung cancer	5e-05	0.000305	CcSEcCtD
Eletriptan—Abdominal pain—Docetaxel—lung cancer	4.98e-05	0.000304	CcSEcCtD
Eletriptan—Body temperature increased—Docetaxel—lung cancer	4.98e-05	0.000304	CcSEcCtD
Eletriptan—Leukopenia—Methotrexate—lung cancer	4.98e-05	0.000304	CcSEcCtD
Eletriptan—Chills—Doxorubicin—lung cancer	4.97e-05	0.000303	CcSEcCtD
Eletriptan—Arrhythmia—Doxorubicin—lung cancer	4.94e-05	0.000301	CcSEcCtD
Eletriptan—Dizziness—Paclitaxel—lung cancer	4.92e-05	0.0003	CcSEcCtD
Eletriptan—Nausea—Cisplatin—lung cancer	4.92e-05	0.0003	CcSEcCtD
Eletriptan—Alopecia—Doxorubicin—lung cancer	4.89e-05	0.000298	CcSEcCtD
Eletriptan—Cough—Methotrexate—lung cancer	4.86e-05	0.000296	CcSEcCtD
Eletriptan—Convulsion—Methotrexate—lung cancer	4.82e-05	0.000294	CcSEcCtD
Eletriptan—Vomiting—Etoposide—lung cancer	4.82e-05	0.000294	CcSEcCtD
Eletriptan—Rash—Etoposide—lung cancer	4.78e-05	0.000291	CcSEcCtD
Eletriptan—Dermatitis—Etoposide—lung cancer	4.78e-05	0.000291	CcSEcCtD
Eletriptan—Headache—Etoposide—lung cancer	4.75e-05	0.000289	CcSEcCtD
Eletriptan—Flatulence—Doxorubicin—lung cancer	4.75e-05	0.000289	CcSEcCtD
Eletriptan—Myalgia—Methotrexate—lung cancer	4.74e-05	0.000289	CcSEcCtD
Eletriptan—Arthralgia—Methotrexate—lung cancer	4.74e-05	0.000289	CcSEcCtD
Eletriptan—Tension—Doxorubicin—lung cancer	4.73e-05	0.000288	CcSEcCtD
Eletriptan—Vomiting—Paclitaxel—lung cancer	4.73e-05	0.000288	CcSEcCtD
Eletriptan—Dysgeusia—Doxorubicin—lung cancer	4.72e-05	0.000288	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	4.7e-05	0.000287	CcSEcCtD
Eletriptan—Rash—Paclitaxel—lung cancer	4.69e-05	0.000286	CcSEcCtD
Eletriptan—Dermatitis—Paclitaxel—lung cancer	4.68e-05	0.000285	CcSEcCtD
Eletriptan—Discomfort—Methotrexate—lung cancer	4.68e-05	0.000285	CcSEcCtD
Eletriptan—Nervousness—Doxorubicin—lung cancer	4.68e-05	0.000285	CcSEcCtD
Eletriptan—Back pain—Doxorubicin—lung cancer	4.66e-05	0.000284	CcSEcCtD
Eletriptan—Headache—Paclitaxel—lung cancer	4.66e-05	0.000284	CcSEcCtD
Eletriptan—Hypersensitivity—Docetaxel—lung cancer	4.64e-05	0.000283	CcSEcCtD
Eletriptan—Muscle spasms—Doxorubicin—lung cancer	4.63e-05	0.000282	CcSEcCtD
Eletriptan—Confusional state—Methotrexate—lung cancer	4.58e-05	0.000279	CcSEcCtD
Eletriptan—Asthenia—Docetaxel—lung cancer	4.52e-05	0.000276	CcSEcCtD
Eletriptan—Nausea—Etoposide—lung cancer	4.5e-05	0.000274	CcSEcCtD
Eletriptan—Ill-defined disorder—Doxorubicin—lung cancer	4.47e-05	0.000272	CcSEcCtD
Eletriptan—Pruritus—Docetaxel—lung cancer	4.46e-05	0.000272	CcSEcCtD
Eletriptan—Nervous system disorder—Methotrexate—lung cancer	4.45e-05	0.000271	CcSEcCtD
Eletriptan—Anaemia—Doxorubicin—lung cancer	4.45e-05	0.000271	CcSEcCtD
Eletriptan—Agitation—Doxorubicin—lung cancer	4.43e-05	0.00027	CcSEcCtD
Eletriptan—Nausea—Paclitaxel—lung cancer	4.42e-05	0.000269	CcSEcCtD
Eletriptan—Skin disorder—Methotrexate—lung cancer	4.41e-05	0.000269	CcSEcCtD
Eletriptan—Hyperhidrosis—Methotrexate—lung cancer	4.39e-05	0.000268	CcSEcCtD
Eletriptan—Malaise—Doxorubicin—lung cancer	4.35e-05	0.000265	CcSEcCtD
Eletriptan—Vertigo—Doxorubicin—lung cancer	4.33e-05	0.000264	CcSEcCtD
Eletriptan—Anorexia—Methotrexate—lung cancer	4.33e-05	0.000264	CcSEcCtD
Eletriptan—Syncope—Doxorubicin—lung cancer	4.32e-05	0.000263	CcSEcCtD
Eletriptan—Leukopenia—Doxorubicin—lung cancer	4.31e-05	0.000263	CcSEcCtD
Eletriptan—Diarrhoea—Docetaxel—lung cancer	4.31e-05	0.000263	CcSEcCtD
Eletriptan—Palpitations—Doxorubicin—lung cancer	4.26e-05	0.000259	CcSEcCtD
Eletriptan—Hypotension—Methotrexate—lung cancer	4.24e-05	0.000259	CcSEcCtD
Eletriptan—Loss of consciousness—Doxorubicin—lung cancer	4.24e-05	0.000258	CcSEcCtD
Eletriptan—Cough—Doxorubicin—lung cancer	4.2e-05	0.000256	CcSEcCtD
Eletriptan—Convulsion—Doxorubicin—lung cancer	4.17e-05	0.000254	CcSEcCtD
Eletriptan—Dizziness—Docetaxel—lung cancer	4.17e-05	0.000254	CcSEcCtD
Eletriptan—Hypertension—Doxorubicin—lung cancer	4.16e-05	0.000254	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Methotrexate—lung cancer	4.14e-05	0.000252	CcSEcCtD
Eletriptan—Insomnia—Methotrexate—lung cancer	4.11e-05	0.00025	CcSEcCtD
Eletriptan—Myalgia—Doxorubicin—lung cancer	4.1e-05	0.00025	CcSEcCtD
Eletriptan—Arthralgia—Doxorubicin—lung cancer	4.1e-05	0.00025	CcSEcCtD
Eletriptan—Anxiety—Doxorubicin—lung cancer	4.09e-05	0.000249	CcSEcCtD
Eletriptan—Paraesthesia—Methotrexate—lung cancer	4.08e-05	0.000249	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	4.07e-05	0.000248	CcSEcCtD
Eletriptan—Discomfort—Doxorubicin—lung cancer	4.05e-05	0.000247	CcSEcCtD
Eletriptan—Dyspnoea—Methotrexate—lung cancer	4.05e-05	0.000247	CcSEcCtD
Eletriptan—Somnolence—Methotrexate—lung cancer	4.04e-05	0.000246	CcSEcCtD
Eletriptan—Dry mouth—Doxorubicin—lung cancer	4.01e-05	0.000244	CcSEcCtD
Eletriptan—Vomiting—Docetaxel—lung cancer	4.01e-05	0.000244	CcSEcCtD
Eletriptan—Dyspepsia—Methotrexate—lung cancer	4e-05	0.000244	CcSEcCtD
Eletriptan—Rash—Docetaxel—lung cancer	3.97e-05	0.000242	CcSEcCtD
Eletriptan—Dermatitis—Docetaxel—lung cancer	3.97e-05	0.000242	CcSEcCtD
Eletriptan—Confusional state—Doxorubicin—lung cancer	3.97e-05	0.000242	CcSEcCtD
Eletriptan—Decreased appetite—Methotrexate—lung cancer	3.95e-05	0.000241	CcSEcCtD
Eletriptan—Headache—Docetaxel—lung cancer	3.95e-05	0.000241	CcSEcCtD
Eletriptan—Oedema—Doxorubicin—lung cancer	3.93e-05	0.00024	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Methotrexate—lung cancer	3.92e-05	0.000239	CcSEcCtD
Eletriptan—Fatigue—Methotrexate—lung cancer	3.92e-05	0.000239	CcSEcCtD
Eletriptan—Pain—Methotrexate—lung cancer	3.88e-05	0.000237	CcSEcCtD
Eletriptan—Shock—Doxorubicin—lung cancer	3.87e-05	0.000236	CcSEcCtD
Eletriptan—Nervous system disorder—Doxorubicin—lung cancer	3.86e-05	0.000235	CcSEcCtD
Eletriptan—Tachycardia—Doxorubicin—lung cancer	3.84e-05	0.000234	CcSEcCtD
Eletriptan—Skin disorder—Doxorubicin—lung cancer	3.82e-05	0.000233	CcSEcCtD
Eletriptan—Hyperhidrosis—Doxorubicin—lung cancer	3.8e-05	0.000232	CcSEcCtD
Eletriptan—Anorexia—Doxorubicin—lung cancer	3.75e-05	0.000228	CcSEcCtD
Eletriptan—Nausea—Docetaxel—lung cancer	3.74e-05	0.000228	CcSEcCtD
Eletriptan—Feeling abnormal—Methotrexate—lung cancer	3.74e-05	0.000228	CcSEcCtD
Eletriptan—Gastrointestinal pain—Methotrexate—lung cancer	3.71e-05	0.000226	CcSEcCtD
Eletriptan—Hypotension—Doxorubicin—lung cancer	3.67e-05	0.000224	CcSEcCtD
Eletriptan—Urticaria—Methotrexate—lung cancer	3.61e-05	0.00022	CcSEcCtD
Eletriptan—Abdominal pain—Methotrexate—lung cancer	3.59e-05	0.000219	CcSEcCtD
Eletriptan—Body temperature increased—Methotrexate—lung cancer	3.59e-05	0.000219	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Doxorubicin—lung cancer	3.58e-05	0.000218	CcSEcCtD
Eletriptan—Insomnia—Doxorubicin—lung cancer	3.56e-05	0.000217	CcSEcCtD
Eletriptan—Paraesthesia—Doxorubicin—lung cancer	3.53e-05	0.000215	CcSEcCtD
Eletriptan—Dyspnoea—Doxorubicin—lung cancer	3.51e-05	0.000214	CcSEcCtD
Eletriptan—Somnolence—Doxorubicin—lung cancer	3.5e-05	0.000213	CcSEcCtD
Eletriptan—Dyspepsia—Doxorubicin—lung cancer	3.46e-05	0.000211	CcSEcCtD
Eletriptan—Decreased appetite—Doxorubicin—lung cancer	3.42e-05	0.000208	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Doxorubicin—lung cancer	3.4e-05	0.000207	CcSEcCtD
Eletriptan—Fatigue—Doxorubicin—lung cancer	3.39e-05	0.000207	CcSEcCtD
Eletriptan—Pain—Doxorubicin—lung cancer	3.36e-05	0.000205	CcSEcCtD
Eletriptan—Constipation—Doxorubicin—lung cancer	3.36e-05	0.000205	CcSEcCtD
Eletriptan—Hypersensitivity—Methotrexate—lung cancer	3.35e-05	0.000204	CcSEcCtD
Eletriptan—Asthenia—Methotrexate—lung cancer	3.26e-05	0.000199	CcSEcCtD
Eletriptan—Feeling abnormal—Doxorubicin—lung cancer	3.24e-05	0.000197	CcSEcCtD
Eletriptan—Gastrointestinal pain—Doxorubicin—lung cancer	3.22e-05	0.000196	CcSEcCtD
Eletriptan—Pruritus—Methotrexate—lung cancer	3.21e-05	0.000196	CcSEcCtD
Eletriptan—Urticaria—Doxorubicin—lung cancer	3.12e-05	0.00019	CcSEcCtD
Eletriptan—Abdominal pain—Doxorubicin—lung cancer	3.11e-05	0.000189	CcSEcCtD
Eletriptan—Body temperature increased—Doxorubicin—lung cancer	3.11e-05	0.000189	CcSEcCtD
Eletriptan—Diarrhoea—Methotrexate—lung cancer	3.11e-05	0.000189	CcSEcCtD
Eletriptan—Dizziness—Methotrexate—lung cancer	3e-05	0.000183	CcSEcCtD
Eletriptan—Hypersensitivity—Doxorubicin—lung cancer	2.9e-05	0.000177	CcSEcCtD
Eletriptan—Vomiting—Methotrexate—lung cancer	2.89e-05	0.000176	CcSEcCtD
Eletriptan—Rash—Methotrexate—lung cancer	2.86e-05	0.000175	CcSEcCtD
Eletriptan—Dermatitis—Methotrexate—lung cancer	2.86e-05	0.000174	CcSEcCtD
Eletriptan—Headache—Methotrexate—lung cancer	2.85e-05	0.000173	CcSEcCtD
Eletriptan—Asthenia—Doxorubicin—lung cancer	2.82e-05	0.000172	CcSEcCtD
Eletriptan—Pruritus—Doxorubicin—lung cancer	2.78e-05	0.00017	CcSEcCtD
Eletriptan—Nausea—Methotrexate—lung cancer	2.7e-05	0.000164	CcSEcCtD
Eletriptan—Diarrhoea—Doxorubicin—lung cancer	2.69e-05	0.000164	CcSEcCtD
Eletriptan—Dizziness—Doxorubicin—lung cancer	2.6e-05	0.000158	CcSEcCtD
Eletriptan—Vomiting—Doxorubicin—lung cancer	2.5e-05	0.000152	CcSEcCtD
Eletriptan—Rash—Doxorubicin—lung cancer	2.48e-05	0.000151	CcSEcCtD
Eletriptan—Dermatitis—Doxorubicin—lung cancer	2.48e-05	0.000151	CcSEcCtD
Eletriptan—Headache—Doxorubicin—lung cancer	2.46e-05	0.00015	CcSEcCtD
Eletriptan—Nausea—Doxorubicin—lung cancer	2.34e-05	0.000142	CcSEcCtD
Eletriptan—HTR1B—Signaling Pathways—IL2—lung cancer	4.39e-06	5.32e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—PIK3CA—lung cancer	4.39e-06	5.32e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—JUN—lung cancer	4.39e-06	5.32e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CCND1—lung cancer	4.37e-06	5.29e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—IL6—lung cancer	4.36e-06	5.29e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—JUN—lung cancer	4.36e-06	5.28e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—NCOA3—lung cancer	4.35e-06	5.27e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—EGFR—lung cancer	4.33e-06	5.24e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CXCL8—lung cancer	4.31e-06	5.23e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—TYMS—lung cancer	4.31e-06	5.22e-05	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—HRAS—lung cancer	4.3e-06	5.21e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—lung cancer	4.29e-06	5.2e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—HRAS—lung cancer	4.28e-06	5.19e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CCND1—lung cancer	4.28e-06	5.18e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—MMP9—lung cancer	4.27e-06	5.17e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—JUN—lung cancer	4.27e-06	5.17e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—GSTP1—lung cancer	4.26e-06	5.17e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—GSTM1—lung cancer	4.26e-06	5.16e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CDKN1A—lung cancer	4.25e-06	5.15e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—TP53—lung cancer	4.24e-06	5.14e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—PTEN—lung cancer	4.24e-06	5.14e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—MMP9—lung cancer	4.24e-06	5.14e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ADCY1—lung cancer	4.23e-06	5.12e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ABCG2—lung cancer	4.23e-06	5.12e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—GSTP1—lung cancer	4.23e-06	5.12e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CDKN1A—lung cancer	4.22e-06	5.12e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—PTEN—lung cancer	4.22e-06	5.11e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—TYMS—lung cancer	4.21e-06	5.1e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PIK3CB—lung cancer	4.2e-06	5.09e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MAP2K1—lung cancer	4.2e-06	5.09e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PIK3CD—lung cancer	4.17e-06	5.06e-05	CbGpPWpGaD
Eletriptan—HTR2B—GPCR downstream signaling—AKT1—lung cancer	4.17e-06	5.05e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PTGS2—lung cancer	4.16e-06	5.05e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—GSTM1—lung cancer	4.16e-06	5.04e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—MMP9—lung cancer	4.15e-06	5.03e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—CAT—lung cancer	4.15e-06	5.03e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ENO2—lung cancer	4.15e-06	5.02e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—HPGDS—lung cancer	4.15e-06	5.02e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—AKT1—lung cancer	4.14e-06	5.02e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CDKN1A—lung cancer	4.14e-06	5.01e-05	CbGpPWpGaD
Eletriptan—HTR1A—GPCR downstream signaling—PIK3CA—lung cancer	4.13e-06	5.01e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—PTEN—lung cancer	4.13e-06	5e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CASP3—lung cancer	4.13e-06	5e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—IL2—lung cancer	4.12e-06	4.99e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PPP2R1B—lung cancer	4.12e-06	4.99e-05	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—IL6—lung cancer	4.12e-06	4.99e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—AKT1—lung cancer	4.11e-06	4.98e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—CAT—lung cancer	4.11e-06	4.98e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—IL6—lung cancer	4.1e-06	4.97e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—lung cancer	4.09e-06	4.95e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—KRAS—lung cancer	4.09e-06	4.95e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—HRAS—lung cancer	4.06e-06	4.92e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—EP300—lung cancer	4.05e-06	4.9e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—CYP1A1—lung cancer	4.04e-06	4.89e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—ABCB1—lung cancer	4.03e-06	4.89e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—AKT1—lung cancer	4.03e-06	4.88e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—GSTT1—lung cancer	4.02e-06	4.87e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—EP300—lung cancer	4.02e-06	4.87e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CCND1—lung cancer	4.02e-06	4.87e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—JUN—lung cancer	4.01e-06	4.86e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—ERCC2—lung cancer	4e-06	4.85e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—ABCB1—lung cancer	4e-06	4.85e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PIK3CB—lung cancer	3.97e-06	4.82e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—GCLC—lung cancer	3.97e-06	4.82e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CYP2A6—lung cancer	3.97e-06	4.82e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—TYMS—lung cancer	3.96e-06	4.8e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—CYP1A1—lung cancer	3.94e-06	4.78e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PTGS2—lung cancer	3.94e-06	4.77e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—EP300—lung cancer	3.94e-06	4.77e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—SRC—lung cancer	3.93e-06	4.77e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—TYMS—lung cancer	3.93e-06	4.76e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—GSTM1—lung cancer	3.92e-06	4.75e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—SRC—lung cancer	3.91e-06	4.74e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—ERCC2—lung cancer	3.91e-06	4.74e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—MMP9—lung cancer	3.9e-06	4.73e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CDKN1A—lung cancer	3.89e-06	4.71e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—IL6—lung cancer	3.88e-06	4.71e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—GSTM1—lung cancer	3.88e-06	4.71e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—PTEN—lung cancer	3.88e-06	4.7e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—VEGFA—lung cancer	3.83e-06	4.64e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—SRC—lung cancer	3.83e-06	4.64e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—VEGFA—lung cancer	3.81e-06	4.61e-05	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—AKT1—lung cancer	3.8e-06	4.6e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—STAT3—lung cancer	3.79e-06	4.6e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—NRAS—lung cancer	3.79e-06	4.59e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—AKT1—lung cancer	3.78e-06	4.58e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—STAT3—lung cancer	3.77e-06	4.57e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ENO1—lung cancer	3.77e-06	4.57e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—NRAS—lung cancer	3.76e-06	4.56e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—PIK3CA—lung cancer	3.75e-06	4.55e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MDM2—lung cancer	3.74e-06	4.53e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—VEGFA—lung cancer	3.73e-06	4.52e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—RAF1—lung cancer	3.73e-06	4.52e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—CYP1A1—lung cancer	3.71e-06	4.5e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—EP300—lung cancer	3.7e-06	4.48e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—STAT3—lung cancer	3.69e-06	4.47e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—ERBB2—lung cancer	3.69e-06	4.47e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—ERCC2—lung cancer	3.68e-06	4.46e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—NRAS—lung cancer	3.68e-06	4.46e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—CYP1A1—lung cancer	3.68e-06	4.46e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—ERCC2—lung cancer	3.65e-06	4.42e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MTOR—lung cancer	3.64e-06	4.41e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PIK3CB—lung cancer	3.64e-06	4.41e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PTEN—lung cancer	3.63e-06	4.4e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—MAPK3—lung cancer	3.63e-06	4.39e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—MAPK3—lung cancer	3.6e-06	4.36e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—SRC—lung cancer	3.6e-06	4.36e-05	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—AKT1—lung cancer	3.58e-06	4.34e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—MAPK3—lung cancer	3.53e-06	4.27e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—MYC—lung cancer	3.53e-06	4.27e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—MYC—lung cancer	3.5e-06	4.25e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—VEGFA—lung cancer	3.5e-06	4.24e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CXCL8—lung cancer	3.5e-06	4.24e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—HRAS—lung cancer	3.47e-06	4.21e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—STAT3—lung cancer	3.47e-06	4.2e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—APOA1—lung cancer	3.46e-06	4.2e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—EP300—lung cancer	3.46e-06	4.2e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—NRAS—lung cancer	3.46e-06	4.19e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—EGFR—lung cancer	3.45e-06	4.18e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PTEN—lung cancer	3.43e-06	4.16e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—MYC—lung cancer	3.43e-06	4.16e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—EGFR—lung cancer	3.43e-06	4.15e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—APOA1—lung cancer	3.38e-06	4.1e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CYP2E1—lung cancer	3.38e-06	4.1e-05	CbGpPWpGaD
Eletriptan—HTR1A—GPCR downstream signaling—AKT1—lung cancer	3.38e-06	4.09e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—EGFR—lung cancer	3.35e-06	4.07e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CASP3—lung cancer	3.35e-06	4.06e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—IL2—lung cancer	3.34e-06	4.05e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—NQO1—lung cancer	3.34e-06	4.05e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—IL6—lung cancer	3.32e-06	4.03e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	3.32e-06	4.02e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—MAPK3—lung cancer	3.31e-06	4.01e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—EP300—lung cancer	3.28e-06	3.97e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—KRAS—lung cancer	3.26e-06	3.95e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CCND1—lung cancer	3.26e-06	3.95e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—JUN—lung cancer	3.25e-06	3.94e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—KRAS—lung cancer	3.24e-06	3.92e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—MYC—lung cancer	3.22e-06	3.9e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—APOA1—lung cancer	3.19e-06	3.86e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—KRAS—lung cancer	3.17e-06	3.84e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MMP9—lung cancer	3.16e-06	3.83e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PIK3CG—lung cancer	3.16e-06	3.83e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—APOA1—lung cancer	3.16e-06	3.83e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—EGFR—lung cancer	3.15e-06	3.82e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CDKN1A—lung cancer	3.15e-06	3.82e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PTEN—lung cancer	3.14e-06	3.81e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PIK3CG—lung cancer	3.09e-06	3.74e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—AKT1—lung cancer	3.07e-06	3.72e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	3.02e-06	3.66e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—STK11—lung cancer	3.01e-06	3.65e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—POMC—lung cancer	3.01e-06	3.65e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—EP300—lung cancer	3e-06	3.63e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—PIK3CA—lung cancer	2.99e-06	3.63e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—KRAS—lung cancer	2.98e-06	3.61e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—PIK3CA—lung cancer	2.97e-06	3.6e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—POMC—lung cancer	2.94e-06	3.56e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—CREBBP—lung cancer	2.93e-06	3.55e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—SRC—lung cancer	2.92e-06	3.53e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—PIK3CA—lung cancer	2.91e-06	3.53e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PIK3CG—lung cancer	2.91e-06	3.52e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—TP53—lung cancer	2.9e-06	3.51e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PIK3CG—lung cancer	2.88e-06	3.49e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—TP53—lung cancer	2.88e-06	3.49e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—CREBBP—lung cancer	2.86e-06	3.47e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—VEGFA—lung cancer	2.84e-06	3.44e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—TP53—lung cancer	2.82e-06	3.41e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—STAT3—lung cancer	2.81e-06	3.41e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—NRAS—lung cancer	2.81e-06	3.4e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—GSTP1—lung cancer	2.79e-06	3.38e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PIK3CD—lung cancer	2.78e-06	3.37e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—HRAS—lung cancer	2.77e-06	3.36e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—POMC—lung cancer	2.77e-06	3.36e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—HRAS—lung cancer	2.75e-06	3.33e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—POMC—lung cancer	2.74e-06	3.33e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—ALB—lung cancer	2.74e-06	3.33e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—PIK3CA—lung cancer	2.74e-06	3.31e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PIK3CD—lung cancer	2.71e-06	3.29e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CAT—lung cancer	2.71e-06	3.29e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—CREBBP—lung cancer	2.7e-06	3.27e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—HRAS—lung cancer	2.69e-06	3.26e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MAPK3—lung cancer	2.69e-06	3.26e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—ALB—lung cancer	2.68e-06	3.25e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—CREBBP—lung cancer	2.67e-06	3.24e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—IL6—lung cancer	2.65e-06	3.21e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—TP53—lung cancer	2.65e-06	3.21e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ABCB1—lung cancer	2.64e-06	3.2e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—IL6—lung cancer	2.63e-06	3.19e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—MYC—lung cancer	2.61e-06	3.17e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—TYMS—lung cancer	2.59e-06	3.14e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—IL6—lung cancer	2.58e-06	3.12e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—PIK3CA—lung cancer	2.56e-06	3.1e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—GSTM1—lung cancer	2.56e-06	3.1e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PIK3CD—lung cancer	2.56e-06	3.1e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—EGFR—lung cancer	2.56e-06	3.1e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PIK3CD—lung cancer	2.53e-06	3.07e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—HRAS—lung cancer	2.53e-06	3.07e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—ALB—lung cancer	2.52e-06	3.06e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—ALB—lung cancer	2.5e-06	3.03e-05	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—AKT1—lung cancer	2.45e-06	2.96e-05	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—AKT1—lung cancer	2.43e-06	2.94e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CYP1A1—lung cancer	2.43e-06	2.94e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PIK3CB—lung cancer	2.42e-06	2.94e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—PIK3CA—lung cancer	2.42e-06	2.94e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—IL6—lung cancer	2.42e-06	2.94e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—KRAS—lung cancer	2.41e-06	2.93e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ERCC2—lung cancer	2.41e-06	2.92e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PTGS2—lung cancer	2.4e-06	2.91e-05	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—AKT1—lung cancer	2.38e-06	2.88e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PIK3CB—lung cancer	2.36e-06	2.87e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PTGS2—lung cancer	2.34e-06	2.84e-05	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—AKT1—lung cancer	2.23e-06	2.71e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PIK3CB—lung cancer	2.23e-06	2.7e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—PIK3CA—lung cancer	2.22e-06	2.69e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PIK3CB—lung cancer	2.21e-06	2.68e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PTGS2—lung cancer	2.21e-06	2.68e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PTGS2—lung cancer	2.19e-06	2.65e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—TP53—lung cancer	2.15e-06	2.6e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PTEN—lung cancer	2.09e-06	2.54e-05	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—AKT1—lung cancer	2.09e-06	2.54e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—APOA1—lung cancer	2.08e-06	2.52e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—HRAS—lung cancer	2.05e-06	2.49e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PTEN—lung cancer	2.04e-06	2.48e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—EP300—lung cancer	2e-06	2.42e-05	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—AKT1—lung cancer	1.98e-06	2.4e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—IL6—lung cancer	1.96e-06	2.38e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—EP300—lung cancer	1.95e-06	2.36e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PTEN—lung cancer	1.93e-06	2.33e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PTEN—lung cancer	1.91e-06	2.31e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PIK3CG—lung cancer	1.9e-06	2.3e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—EP300—lung cancer	1.84e-06	2.23e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—EP300—lung cancer	1.82e-06	2.21e-05	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—AKT1—lung cancer	1.81e-06	2.2e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—POMC—lung cancer	1.81e-06	2.19e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—CREBBP—lung cancer	1.76e-06	2.14e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PIK3CD—lung cancer	1.67e-06	2.03e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ALB—lung cancer	1.65e-06	2e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—PIK3CA—lung cancer	1.48e-06	1.79e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PIK3CB—lung cancer	1.46e-06	1.77e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PTGS2—lung cancer	1.44e-06	1.75e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—PIK3CA—lung cancer	1.44e-06	1.75e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—PIK3CA—lung cancer	1.36e-06	1.65e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—PIK3CA—lung cancer	1.35e-06	1.63e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PTEN—lung cancer	1.26e-06	1.53e-05	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—AKT1—lung cancer	1.21e-06	1.46e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—EP300—lung cancer	1.2e-06	1.46e-05	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—AKT1—lung cancer	1.18e-06	1.43e-05	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—AKT1—lung cancer	1.11e-06	1.34e-05	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—AKT1—lung cancer	1.1e-06	1.33e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—PIK3CA—lung cancer	8.88e-07	1.08e-05	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—AKT1—lung cancer	7.26e-07	8.79e-06	CbGpPWpGaD
